Rationale for the development and current status of calcitriol in androgen-independent prostate cancer

Tomasz (Tom) Beer, Anne Myrthue, Kristine M. Eilers

    Research output: Contribution to journalArticle

    18 Citations (Scopus)

    Abstract

    Calcitriol, the principal active metabolite of vitamin D, has significant antineoplastic activity in pre-clinical models of prostate cancer and many other tumor types. Reported mechanisms of activity include inhibition of proliferation and cell cycle arrest, induction of apoptosis, and reduction of invasiveness and angiogenesis. Different mechanisms may be responsible in different tumor types and under different experimental conditions. Importantly, preclinical data suggest that calcitriol acts in a synergistic and/or additive manner when combined with antineoplastic agents that are relevant to prostate cancer, including dexamethasone and several classes of cytotoxic agents. The antineoplastic effects of calcitriol occur at concentrations that substantially exceed the normal physiologic range and cannot be safely achieved with conventional daily dosing. Intermittent administration of calcitriol has allowed significant dose escalation. In combination with weekly docetaxel, the agent produced encouraging results in a single-institution phase II study. An international placebo-controlled randomized trial that is currently under way will provide more robust information about the safety and efficacy of this combination.

    Original languageEnglish (US)
    Pages (from-to)28-32
    Number of pages5
    JournalWorld Journal of Urology
    Volume23
    Issue number1
    DOIs
    StatePublished - Feb 2005

    Fingerprint

    Calcitriol
    Androgens
    Prostatic Neoplasms
    docetaxel
    Antineoplastic Agents
    Antineoplastic Combined Chemotherapy Protocols
    Cytotoxins
    Cell Cycle Checkpoints
    Vitamin D
    Dexamethasone
    Neoplasms
    Reference Values
    Randomized Controlled Trials
    Placebos
    Apoptosis
    Safety

    Keywords

    • Calcitriol
    • Prostate cancer
    • Vitamin D

    ASJC Scopus subject areas

    • Urology

    Cite this

    Rationale for the development and current status of calcitriol in androgen-independent prostate cancer. / Beer, Tomasz (Tom); Myrthue, Anne; Eilers, Kristine M.

    In: World Journal of Urology, Vol. 23, No. 1, 02.2005, p. 28-32.

    Research output: Contribution to journalArticle

    @article{5686b97ee15b44d39c447a912e23f510,
    title = "Rationale for the development and current status of calcitriol in androgen-independent prostate cancer",
    abstract = "Calcitriol, the principal active metabolite of vitamin D, has significant antineoplastic activity in pre-clinical models of prostate cancer and many other tumor types. Reported mechanisms of activity include inhibition of proliferation and cell cycle arrest, induction of apoptosis, and reduction of invasiveness and angiogenesis. Different mechanisms may be responsible in different tumor types and under different experimental conditions. Importantly, preclinical data suggest that calcitriol acts in a synergistic and/or additive manner when combined with antineoplastic agents that are relevant to prostate cancer, including dexamethasone and several classes of cytotoxic agents. The antineoplastic effects of calcitriol occur at concentrations that substantially exceed the normal physiologic range and cannot be safely achieved with conventional daily dosing. Intermittent administration of calcitriol has allowed significant dose escalation. In combination with weekly docetaxel, the agent produced encouraging results in a single-institution phase II study. An international placebo-controlled randomized trial that is currently under way will provide more robust information about the safety and efficacy of this combination.",
    keywords = "Calcitriol, Prostate cancer, Vitamin D",
    author = "Beer, {Tomasz (Tom)} and Anne Myrthue and Eilers, {Kristine M.}",
    year = "2005",
    month = "2",
    doi = "10.1007/s00345-004-0476-y",
    language = "English (US)",
    volume = "23",
    pages = "28--32",
    journal = "World Journal of Urology",
    issn = "0724-4983",
    publisher = "Springer Verlag",
    number = "1",

    }

    TY - JOUR

    T1 - Rationale for the development and current status of calcitriol in androgen-independent prostate cancer

    AU - Beer, Tomasz (Tom)

    AU - Myrthue, Anne

    AU - Eilers, Kristine M.

    PY - 2005/2

    Y1 - 2005/2

    N2 - Calcitriol, the principal active metabolite of vitamin D, has significant antineoplastic activity in pre-clinical models of prostate cancer and many other tumor types. Reported mechanisms of activity include inhibition of proliferation and cell cycle arrest, induction of apoptosis, and reduction of invasiveness and angiogenesis. Different mechanisms may be responsible in different tumor types and under different experimental conditions. Importantly, preclinical data suggest that calcitriol acts in a synergistic and/or additive manner when combined with antineoplastic agents that are relevant to prostate cancer, including dexamethasone and several classes of cytotoxic agents. The antineoplastic effects of calcitriol occur at concentrations that substantially exceed the normal physiologic range and cannot be safely achieved with conventional daily dosing. Intermittent administration of calcitriol has allowed significant dose escalation. In combination with weekly docetaxel, the agent produced encouraging results in a single-institution phase II study. An international placebo-controlled randomized trial that is currently under way will provide more robust information about the safety and efficacy of this combination.

    AB - Calcitriol, the principal active metabolite of vitamin D, has significant antineoplastic activity in pre-clinical models of prostate cancer and many other tumor types. Reported mechanisms of activity include inhibition of proliferation and cell cycle arrest, induction of apoptosis, and reduction of invasiveness and angiogenesis. Different mechanisms may be responsible in different tumor types and under different experimental conditions. Importantly, preclinical data suggest that calcitriol acts in a synergistic and/or additive manner when combined with antineoplastic agents that are relevant to prostate cancer, including dexamethasone and several classes of cytotoxic agents. The antineoplastic effects of calcitriol occur at concentrations that substantially exceed the normal physiologic range and cannot be safely achieved with conventional daily dosing. Intermittent administration of calcitriol has allowed significant dose escalation. In combination with weekly docetaxel, the agent produced encouraging results in a single-institution phase II study. An international placebo-controlled randomized trial that is currently under way will provide more robust information about the safety and efficacy of this combination.

    KW - Calcitriol

    KW - Prostate cancer

    KW - Vitamin D

    UR - http://www.scopus.com/inward/record.url?scp=15844421214&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=15844421214&partnerID=8YFLogxK

    U2 - 10.1007/s00345-004-0476-y

    DO - 10.1007/s00345-004-0476-y

    M3 - Article

    C2 - 15668801

    AN - SCOPUS:15844421214

    VL - 23

    SP - 28

    EP - 32

    JO - World Journal of Urology

    JF - World Journal of Urology

    SN - 0724-4983

    IS - 1

    ER -